Oral oncology最新文献

{"title":"Commentary on, “Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107285","DOIUrl":"10.1016/j.oraloncology.2025.107285","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107285"},"PeriodicalIF":4.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating observer reliability and diagnostic accuracy of CT-LEFAT criteria for post-treatment head and neck lymphedema: A prospective blinded comparative analysis","authors":"Natalie A. West ,&nbsp;Serageldin K. Attia ,&nbsp;Zaphanlene Kaffey ,&nbsp;Cem Dede ,&nbsp;Samuel L. Mulder ,&nbsp;Dina M. El-Habashy ,&nbsp;Roger Neuberger ,&nbsp;Mohamed A. Naser ,&nbsp;Steven J. Frank ,&nbsp;Shitong Mao ,&nbsp;Holly McMillan ,&nbsp;Brad Smith ,&nbsp;David Rosenthal ,&nbsp;Stephen Y. Lai ,&nbsp;Katherine A. Hutcheson ,&nbsp;Amy C. Moreno ,&nbsp;Clifton D. Fuller ,&nbsp;MD Anderson Head and Neck Cancer Symptom Working Group","doi":"10.1016/j.oraloncology.2025.107265","DOIUrl":"10.1016/j.oraloncology.2025.107265","url":null,"abstract":"<div><h3>Background</h3><div>Radiation-associated lymphedema and fibrosis (LEF) is a significant toxicity following radiation therapy (RT) for head and neck cancer (HNC) patients. Recently, the CT Lymphedema and Fibrosis Assessment Tool (CT-LEFAT) was developed to standardize LEF diagnosis through fat stranding visualized on CT. This study aims to evaluate the inter-observer reliability and diagnostic accuracy of the CT-LEFAT criteria.</div></div><div><h3>Materials and Methods</h3><div>This study retrospectively evaluated 26 HNC patients treated with RT that received a minimum of two contrast-enhanced CT scans. Qualitative review was conducted by five physician raters to assess the fat stranding observed on CT according to the CT-LEFAT criteria. Fleiss’ kappa analysis was used to assess the inter- and intra-rater reliability, and Receiver Operating Characteristic (ROC) Area Under the Curve (AUC) analysis was used to evaluate diagnostic accuracy.</div></div><div><h3>Results</h3><div>The inter-rater reliability across the six CT-LEFAT regions generally indicated a slight to fair agreement across all raters (0.04 ≤ kappa ≤ 0.36). Intra-observer agreement was generally fair to moderate (overall kappa = 0.44). The ROC AUC analysis varied based on aggregation method used (0.60 ≤ average AUC ≤ 0.70).</div></div><div><h3>Conclusion</h3><div>This specific use-case evaluating CT-LEFAT criteria displays limited performance. This suggests that additional materials, such as further training, refinement of imaging methods, or other processes may be required before achieving clinically-ready diagnostic performance of LEF diagnosis.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107265"},"PeriodicalIF":4.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review","authors":"Susmita Chennareddy ,&nbsp;Sida Chen ,&nbsp;Carrie Levinson ,&nbsp;Eric M. Genden ,&nbsp;Marshall R. Posner ,&nbsp;Scott A. Roof","doi":"10.1016/j.oraloncology.2025.107262","DOIUrl":"10.1016/j.oraloncology.2025.107262","url":null,"abstract":"<div><h3>Objective</h3><div>Circulating tumor DNA (ctDNA) has emerged as a promising tool in the treatment of HPV-associated oropharyngeal squamous cell cancer (OPSCC). This systematic review sought to answer the question: what is the current role of ctDNA in the diagnosis, treatment, and surveillance of HPV-associated OPSCC?</div></div><div><h3>Data sources</h3><div>Medline (Ovid), Embase (Ovid), Scopus.</div></div><div><h3>Review methods</h3><div>Original articles studying the role of ctDNA in the diagnosis or surveillance of HPV-associated OPSCC were eligible for inclusion. Two authors independently reviewed studies for inclusion and abstracted data, including study design, characterization of liquid biopsy technology, and diagnostic outcomes.</div></div><div><h3>Results</h3><div>After a preliminary screening of 441 studies, 23 were selected for inclusion. Ten studies were conducted retrospectively, and 13 were conducted prospectively. In these studies, diagnostic testing included plasma-based droplet digital polymerase chain reaction (ddPCR, n = 13), quantitative PCR (qPCR, n = 4), digital PCR (dPCR, n = 3), next-generation sequencing (NGS) (n = 3), or a ctDNA detection kit (n = 1). Diagnostic outcomes were reported for pre-diagnosis (n = 1), pre-treatment (n = 17), during treatment (n = 6), and surveillance/recurrence (n = 11) timepoints. Test sensitivities ranged from 20.6 %–100 % pre-treatment and 72 %–100 % during surveillance, while test specificities ranged from 95 %–100 % pre-treatment and 87.2 %–100 % during surveillance.</div></div><div><h3>Conclusion</h3><div>The majority of studied ctDNA technologies allow for detection of HPV-associated OPSCC with high diagnostic accuracy. However, heterogeneity is introduced by test type and assay used. These findings highlight the utility, as well as limitations, of ctDNA in the diagnosis, treatment monitoring, and surveillance of HPV-associated OPSCC. Future studies and clinical consensus will need to address acceptable diagnostic accuracy thresholds for clinical use.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107262"},"PeriodicalIF":4.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological outcomes of pathological extranodal extension (pENE) in oral squamous cell carcinoma (OSCC): A proposal to refine the current staging","authors":"Hemant Nemade ,&nbsp;Abhinav Thaduri ,&nbsp;Jonathan T Gondi ,&nbsp;Sravan Kumar Chava ,&nbsp;Anil Kumar ,&nbsp;Sahithi Shilpa Arya ,&nbsp;L.M.Chandra Sekara Rao S","doi":"10.1016/j.oraloncology.2025.107281","DOIUrl":"10.1016/j.oraloncology.2025.107281","url":null,"abstract":"<div><h3>Background</h3><div>Extranodal extension (ENE) is an important prognostic factor in oral squamous cell carcinoma (OSCC), often associated with poor survival outcomes. However, the current nodal (N) staging system may need to be revised to reflect the prognosis. Emerging evidence suggests that the number of positive lymph nodes may offer improved prognostic accuracy. This study evaluates the outcomes of OSCC patients with pathological ENE (pENE) and explores the prognostic significance of absolute positive lymph node count.</div></div><div><h3>Materials and Methods</h3><div>This retrospective cohort study analyzed 640 OSCC patients with pENE who underwent curative-intent surgery and standard adjuvant therapies between May 2015 and December 2021. Receiver Operating Characteristic (ROC) curve analysis was performed to identify a cutoff for the number of positive lymph nodes predicting overall survival (OS). Survival analyses were conducted using Kaplan-Meier curves, and Cox proportional hazards regression was used to identify independent predictors of OS and disease-free survival (DFS).</div></div><div><h3>Results</h3><div>In the entire cohort, the median DFS was 16 months (95 % CI: 12–19), and the mean OS was 57 months (95 % CI: 52–62). ROC analysis identified four positive lymph nodes as the optimal cutoff for predicting OS (AUC = 0.562, p = 0.01), with a sensitivity of 46.3 % and specificity of 65.2 %. Patients with &gt; 4 positive lymph nodes had significantly poorer outcomes compared to those with ≤ 4 nodes: median DFS was 9 months vs. 21 months (p &lt; 0.001), and mean OS was 26 months vs. 61 months (p &lt; 0.001). Multivariate Cox regression confirmed the number of positive lymph nodes as an independent predictor for OS (HR = 0.6, p &lt; 0.001) and DFS (HR = 0.5, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Patients with pENE and &gt; four positive lymph nodes have significantly worse survival outcomes despite standard adjuvant therapies. This highlights the need for improved risk stratification in the current nodal staging system. These findings suggest incorporating lymph node burden into staging frameworks could improve prognostic accuracy.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107281"},"PeriodicalIF":4.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-induced sarcomas of the craniofacial region: A systematic review","authors":"Ann-Kristin Struckmeier ,&nbsp;Martin Gosau ,&nbsp;Ralf Smeets","doi":"10.1016/j.oraloncology.2025.107282","DOIUrl":"10.1016/j.oraloncology.2025.107282","url":null,"abstract":"<div><h3>Background</h3><div>Radiation-induced sarcomas (RIS) are rare entities that have been studied infrequently in large cohorts, with most data derived from case reports or small series. This study aims to systematically evaluate existing data to synthesize and consolidate current knowledge.</div></div><div><h3>Methods</h3><div>An electronic literature search was conducted using PubMed and the Cochrane Library. The search included studies and case reports with clinico-histopathological and survival data on craniofacial RIS.</div></div><div><h3>Results</h3><div>Among 1237 studies identified, 143 studies with 701 patients were included. The average patient age was 48 years, with men nearly twice as likely to develop RIS. RIS had an average latency period of 12 years, with an average radiation dose of 63 Gy. Radiation-induced osteosarcomas (42.1 %) were most common, followed by fibrosarcomas (21.1 %). Nasopharyngeal carcinoma (53.0 %) and retinoblastoma (10.3 %) were the most prevalent primary tumors. 5.4 % of patients received radiotherapy for benign disease. The average latency period in this group was approximately 1.5 times longer than that observed in the group with malignancies; however, the average radiation dose was also approximately 15 Gy lower. Local recurrences occurred after an average of 16 months. The 1-, 2-, and 5-year survival rates were 67.8 %, 47.1 %, and 25.0 %, respectively. Surgical therapy showed the best survival rates (33.3 % after 5 years) while isolated chemotherapy yielded the lowest (0.0 %).</div></div><div><h3>Conclusion</h3><div>The prognosis for craniofacial RIS remains poor despite aggressive treatment. Surgical intervention is the primary therapeutic approach, but optimal treatment regimens and the role of (neo-)adjuvant therapies require further investigation. This study underscores the complexity of managing RIS and highlights the need for ongoing research to improve outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107282"},"PeriodicalIF":4.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial","authors":"Nan Lin ,&nbsp;Xueyan Zhou ,&nbsp;Yusha Wang ,&nbsp;Jing Zhou ,&nbsp;Yueyi Li ,&nbsp;Keqin Tan ,&nbsp;Jia Li ,&nbsp;Yimin Li ,&nbsp;Linghong Guo ,&nbsp;Yang Liu ,&nbsp;Xia Wang ,&nbsp;Lei Zhao ,&nbsp;Tao Zhang ,&nbsp;Tingting Dai ,&nbsp;Ning Zhu ,&nbsp;Zhiwen Long ,&nbsp;Xin Wu ,&nbsp;Hong Zhang ,&nbsp;Xuelei Ma","doi":"10.1016/j.oraloncology.2025.107269","DOIUrl":"10.1016/j.oraloncology.2025.107269","url":null,"abstract":"<div><div>Nasopharyngeal carcinoma is prevalent in Southern China and Southeast Asia, which is effectively managed through chemoradiotherapy for locoregionally advanced cases (LA-NPC). Despite current guidelines endorsing various rehabilitation regimens for surgery, evidence supporting the benefits of rehabilitation during systemic radiotherapy is scarce. Thus we introduce the Enhanced Recovery After Radiotherapy (ERAR) concept. We enrolled patients with stage III to IVA LA-NPC in this study. The ERAR group received comprehensive interventions encompassing nursing, oral care, psychology support, rehabilitation, nutrition, and skin health throughout their radiotherapy. The standard care group received conventional radiotherapy rehabilitation. Outcomes were evaluated at baseline, the 17th and 33rd radiotherapy sessions. Generalized estimating equations were used to evaluate group by time effects on the outcomes, controlling for key covariates. A total of 104 LA-NPC patients with a mean age of 49.2 ± 10.9 years were enrolled in the study group from August 2021 to September 2023. The ERAR group showed significant improvements in quality of life (<em>P</em> = 0.014), Hospital Anxiety and Depression Scale (HADS) anxiety (<em>P</em> &lt; 0.001), HADS depression (<em>P</em> &lt; 0.001), distress thermometer (<em>P</em> = 0.049), NRS2002 (<em>P</em> = 0.040), weight loss (<em>P</em> &lt; 0.001), and Oral Health Impact Profile-14 (OHIP-14) (<em>P</em> = 0.040) scores outperforming the standard care group at all measured time points. The ERAR protocol significantly mitigates acute radiation-induced toxicities in LA-NPC patients. This study is anticipated to serve as a reference for clinicians and encourage the adoption of a standardized protocol aimed at facilitating rapid recovery post-radiotherapy.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107269"},"PeriodicalIF":4.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery","authors":"Filippo Marchi ,&nbsp;Francesca Del Bon ,&nbsp;Francesco Chu ,&nbsp;Claudio Sampieri ,&nbsp;Elisa Bellini ,&nbsp;Davide Lancini ,&nbsp;Stefano Zorzi ,&nbsp;Laura Ruiz-Sevilla ,&nbsp;Marta De Vecchi ,&nbsp;Aurora Pinacoli ,&nbsp;Giacomo Pietrobon ,&nbsp;Rosa-Delia Ramirez ,&nbsp;Pietro Benzi ,&nbsp;Jacopo Di Domenico ,&nbsp;Francesc Xavier Avilés-Jurado ,&nbsp;Marta Filauro ,&nbsp;Gabriele Zigliani ,&nbsp;Francesco Mora ,&nbsp;Alessandra Sordi ,&nbsp;Claudia Montenegro ,&nbsp;Giorgio Peretti","doi":"10.1016/j.oraloncology.2025.107264","DOIUrl":"10.1016/j.oraloncology.2025.107264","url":null,"abstract":"<div><h3>Background</h3><div>The current TNM staging system does not fully address the variations in glottic squamous cell carcinoma (SCC) extension and subsites involvement, especially if treated with transoral laser microsurgery (TOLMS). This study aims to evaluate the oncologic outcomes after TOLMS in intermediate-advanced glottic SCC, stratified by prognostic subcategories based on anatomical tumor extension.</div></div><div><h3>Methods</h3><div>This retrospective multicentric study analyzed 637 previously untreated patients with pT2-T3 glottic SCC treated by TOLMS following the same policies at four tertiary European centers. Patients were stratified into 5 subcategories (III, IV, Va, Vb, VI) based on three-dimensional local tumor extension, a refined definition of the previous classification proposed by Piazza et al.</div></div><div><h3>Results</h3><div>Out of 637 patients, 453 (71 %) were pT2, and 184 (29 %) pT3. The 5-year disease-specific survival for the entire cohort was 91 %, LCL 81 %, and LP 87 %. Subcategories Va (anterior paraglottic space [PGS] involvement) and Vb (posterior PGS involvement) showed significantly poorer disease-specific survival (Va: 91 %, Vb: 80 %) and local control with laser alone (Va: 76 %, Vb: 68 %) compared to subcategories III (tumors extending superficially to the supra- and/or subglottis) and IV (tumors infiltrating the vocal muscle). Tumors with posterior PGS involvement demonstrated the highest risk of local recurrence and total laryngectomy (HR: 3.70).</div></div><div><h3>Conclusion</h3><div>TOLMS is a viable treatment option for T2-T3 glottic SCC, offering high rates of laryngeal preservation and favorable oncologic outcomes in well-selected patients. Stratification based on tumor subsites involvement provides critical prognostic insights, with posterior PGS invasion serving as a key risk factor for poorer outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107264"},"PeriodicalIF":4.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemoradiation for patients with resectable locally advanced oral cavity squamous cell carcinoma: Results of the prospective INVERT clinical trial","authors":"Maximilian Fleischmann ,&nbsp;Alexander Kristen ,&nbsp;Ria Winkelmann ,&nbsp;Iris Burck ,&nbsp;Andreas Weigert ,&nbsp;Christian Issing ,&nbsp;Markus Diefenhardt ,&nbsp;Daniel Martin ,&nbsp;Christian Brandts ,&nbsp;Franz Rödel ,&nbsp;Panagiotis Balermpas ,&nbsp;Jens von der Grün ,&nbsp;Philipp Thönissen ,&nbsp;Claus Rödel ,&nbsp;Shahram Ghanaati","doi":"10.1016/j.oraloncology.2025.107252","DOIUrl":"10.1016/j.oraloncology.2025.107252","url":null,"abstract":"<div><h3>Objective</h3><div>The INVERT trial is a prospective, monocentric, proof-of-principle phase 2clinical trial evaluating the safety and efficacy of neoadjuvant chemoradiation (CRT) inpatients with resectable, locally advanced oral cavity squamous cell carcinoma (LAOCSCC).</div></div><div><h3>Methods</h3><div>Eligible patients received intensity-modulated radiotherapy (IMRT) to primarytumor and nodal volumes (60/54/50 Gy in 30 fractions) with concomitant platinumbasedchemotherapy. Surgery was performed 6–8 weeks after CRT. Primary endpointwas the pathological complete response (pCR = ypT0N0) rate. Secondary endpointsincluded R0 resection rate, surgical complications, oncological outcomes, and qualityof life.</div></div><div><h3>Results</h3><div>Between 02/2012 and 09/2022, 28 UICC Stage (7th edition) IVA-IVB LAOCSCCpatients were enrolled; 92.1 % showed mandibular involvement. All patientsreceived the the full IMRT dose of 60 Gy. For all cisplatin-eligible patients, the mediancumulative dose was 200 mg/m2 BSA. In the intention-to-treat population, the pCR ratewas 46.4 % (n = 13) but did not met the primary endpoint. In total, we recorded 384adverse events (AEs) of any grade and 109 AEs ≥ grade 3 according to CTCAE (nograde 5). Surgical complications were primarily wound healing disorders and postbleeding, with no grade 4 or 5 events. At a median follow-up of 28.5 months,progression-free survival (PFS), local control (LC), freedom from distant failure (DF),and overall survival (OS) were 60.7 %, 89.3 %, 82.1 %, and 64.3 %, respectively. pCRPowered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporationsignificantly correlated with improved PFS (p = 0.010) and OS (p = 0.021).</div></div><div><h3>Conclusion</h3><div>Neoadjuvant CRT is feasible and safe, achieving high pCR rates in LAOCSCC.pCR was associated with improved outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107252"},"PeriodicalIF":4.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis","authors":"Luca Canali ,&nbsp;Elena Russo ,&nbsp;Sofia Pangallo ,&nbsp;Francesco Bussu ,&nbsp;Giuseppe Spriano ,&nbsp;Giuseppe Mercante ,&nbsp;Fabio Ferreli","doi":"10.1016/j.oraloncology.2025.107270","DOIUrl":"10.1016/j.oraloncology.2025.107270","url":null,"abstract":"<div><h3>Objectives</h3><div>To systematically analyze the regional disease control of nasal vestibule squamous cell carcinoma (NVSCC) after primary treatment.</div></div><div><h3>Methods</h3><div>The study was performed according to the PRISMA guidelines, searching on Scopus, PubMed/MEDLINE, Cochrane Library, and Google Scholar databases.</div></div><div><h3>Results</h3><div>A total of 37 studies with 1861 patients (70.5 % males; median age of 58.2 years) were included. Overall, the cumulative regional recurrence (RR) rate was 10.7 % (95 %CI: 8.4 %–13.5 %) with a median follow-up of 51.7 months. The RR rate in clinical node negative patients who didn’t undergo any elective neck treatment was 13.7 % (n = 548, 95 %CI: 9.7 %–19.0 %). When stratified by T stage, regardless of the classification used, RR rate was 10.4 % (n = 750, 95 % CI: 7.9 %–13.5 %) for T1-T2 tumors and 25.5 % (n = 102, 95 % CI: 16.4 %–37.4 %) for T3-T4 tumors.</div></div><div><h3>Conclusion</h3><div>Elective neck treatment does not seem justified in patients with early-stage primary NVSCC. However, for locally advanced tumors, elective neck treatment should be strongly considered.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107270"},"PeriodicalIF":4.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx","authors":"Giovanni Motta ,&nbsp;Carlo Magno ,&nbsp;Ludovica Castagna ,&nbsp;Thibauld De Berardinis ,&nbsp;Arianna Di Stadio","doi":"10.1016/j.oraloncology.2025.107260","DOIUrl":"10.1016/j.oraloncology.2025.107260","url":null,"abstract":"<div><h3>Background</h3><div>Pleomorphic adenomas are benign tumors that typically arise from the salivary glands, most commonly the parotid gland. However, they can also occur in minor salivary glands and ectopic salivary tissue, and in very rare cases, these tumors arise in the nasopharynx.</div></div><div><h3>Case report</h3><div>We present a rare case of a pleomorphic adenoma originating from the nasopharynx in a 49-year-old female patient. The patient was affected by snoring, bilateral nasal obstruction, and bilateral otitis media with effusion. Radiological investigations identified a well-defined mass in the nasopharynx. The tumor was successfully removed via a transoral approach, and histopathological examination confirmed the diagnosis of pleomorphic adenoma.</div></div><div><h3>Conclusion</h3><div>This case highlights the importance of considering pleomorphic adenoma in the differential diagnosis of nasopharyngeal masses, even though rarely occurs in this location. Complete surgical excision with preservation of the tumor capsule is crucial to prevent recurrence.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"164 ","pages":"Article 107260"},"PeriodicalIF":4.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}